Portal de investigación
Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Garcia-Martinez, A
- Fuentes-Fayos, AC
- Fajardo, C
- Lamas, C
- Lopez-Munoz, B
- Aranda, I
- Luque, RM
- Pico, A
Grupos
Abstract
The potential role of miRNAs in the silencing mechanisms of pituitary neuroendocrine tumors (PitNETs) has not been addressed. The aim of the present study was to evaluate the expression levels and the potential associated role of some miRNAs, pathways, and transcription factors in the silencing mechanisms of corticotroph tumors (CTs). Accordingly, the expression of miR-375, miR-383, miR-488, miR-200a and miR-103; ofPKA,MAP3K8,MEK,MAPK3,NGFIB,NURR1,PITX1, andSTAT3were analyzed via qRT-PCR in 23 silent and 24 functioning CTs. miR-200a and miR-103 showed significantly higher expression in silent than in functioning CTs, even after eliminating the bias of tumor size, therefore enabling the differentiation between the two variants. Additionally, miR-383 correlated negatively withTBX19in silent CTs, a transcription factor related with the processing ofPOMCthat can participate in the silencing mechanisms of CTs. Finally, the gene expression levels of miR-488, miR-200a, and miR-103 were significantly higher in macroadenomas (functioning and silent) than in microadenomas. The evidence from this study indicates that miRNAs could be involved in the pathophysiology of CTs. The translational implications of these findings suggest that pharmacological treatments specifically targeting these miRNAs could become a promising therapeutic option for these patients.
Datos de la publicación
- ISSN/ISSNe:
- 2077-0383, 2077-0383
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.3390/jcm9061838
- PubMed:
- 32545591
Journal of clinical medicine MDPI AG
Citas Recibidas en Web of Science: 6
Documentos
- No hay documentos
Filiaciones
Keywords
- pituitary neuroendocrine tumors; corticotroph tumors; miRNA; transcriptional regulation
Proyectos y Estudios Clínicos
ESTUDIO FASE III, MULTICENTRICO, ALEATORIZADO, DOBLE CIEGO DE 48 SEMANAS, CON UN PERIDO INICIAL DE 12 SEMANAS CONTROLADO CON PLACEBO, PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE OSILODROSTAT EN PACIENTES CON ENFERMEDADES DE CUSHING.
Investigador Principal: ROSA CÁMARA GÓMEZ
CLCI699C2302 . 2016
ESTUDIO DE EXTENSIÓN, MULTICÉNTRICO, ABIERTO PARA EVALUAR LA SEGURIDAD A LARGO PLAZO EN PACIENTES CON SÍNDROME DE CUSHING ENDÓGENO QUE HAYAN COMPLETADO UN ESTUDIO ANTERIOR DE OSILODROSTAT (LCI699) PATROCINADO POR NOVARTIS Y QUE EL INVESTIGADOR CONSIDERE QUE SE ESTÁN BENEFICIANDO DEL TRATAMIENTO CONTINUADO CON OSILODROSTAT.
Investigador Principal: ROSA CÁMARA GÓMEZ
CLCI699C2X01B . 2018
ESTUDIO OBSERVACIONAL, TRASVERSAL Y MULTICÉNTRICO PARA VALORAR EL CUMPLIMENTO TERAPÉUTICO CON SOMAVERT® EN PACIENTES CON ACROMEGALIA EN CONDICIONES DE PRÁCTICA CLÍNICA HABITUAL.
Investigador Principal: ROSA CÁMARA GÓMEZ
PFI-PEG-2014-01 . 2015
ESTUDIO MUNDIAL SOBRE EL CONTROL Y LAS COMPLICACIONES DEL HIPOTITUITARISMO (HYPOCCS).
Investigador Principal: JUAN FRANCISCO MERINO TORRES
B9R-MC-GDGA . 2011
Cita
Garcia A,Fuentes AC,Fajardo C,Lamas C,CAMARA R,Lopez B,Aranda I,Luque RM,Pico A. Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors. J. Clin. Med. 2020. 9. (6):1838. IF:4,241. (1).